Rezolute To Participate In Upcoming Investor Conferences
Event: Cantor Global Healthcare Conference
Date: September 9-11, 2026
Event: H.C. Wainwright 28th Annual Global Investment Conference
Date: September 14-16, 2026
Event: Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 14-16, 2026
Management will be participating in fireside chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Cantor, H.C. Wainwright, and Morgan Stanley representatives.
About Rezolute, Inc.
Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company's antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit .
Rezolute Contacts:
Christen Baglaneas
...
508-272-6717
Carrie McKim
...
336-608-9706
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment